Perjeta.com site quick analysis
Share your opinion about Perjeta.com:
Search engine results page snippet (SERP)
This is how Perjeta.com appears when you search for it:
perjeta.com
Learn about PERJETA®, a neoadjuvant and metastatic breast cancer treatment for patients with HER2-positive breast cancer. What does PERJETA treat? PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival. • The safety of PERJETA in combination with doxorubicin-containing regimens has not been established • The safety of PERJETA administered for greater than 6 cycles for early-stage breast cancer has not been established. Important Safety Information • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure) • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects — If you think you may be pregnant, you should contact your healthcare provider immediately — If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555 • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA • Other possible serious side effects of PERJETA therapy include: — Infusion-related reactions — Severe allergic reactions (hypersensitivity reactions/anaphylaxis) • PERJETA has only been shown to work in people with HER2-positive breast cancer • The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are: — Diarrhea — Hair loss — Low levels of white blood cells with or without a fever — Nausea — Feeling tired — Rash — Damage to the nerves (numbness, tingling, pain in hands/feet) • The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are: — Hair loss — Diarrhea — Nausea — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever — Low platelet count — Low levels of red blood cells You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.
General website information
A quick breakdown about the Perjeta.com website can be found further down:
Aspect | Summary |
---|
Website load speed: | 3.2493s poor |
Number of (outgoing) links: | 44 |
HTML size: | 56 kilobytes Too heavy |
meta-tag Generator | Drupal 7 (http://drupal.org) |
Perjeta.com HTTP headers
HTTP/1.1 200 OK
Expires: Sun, 19 Nov 1978 05:00:00 GMT
Last-Modified: Thu, 11 May 2017 14:40:46 +0000
Cache-Control: no-cache, must-revalidate, post-check=0, pre-check=0
ETag: "1494513646"
Content-Language: en
Link: </node/49>; rel="shortlink",</patient>; rel="canonical"
Content-Type: text/html; charset=utf-8
Content-Length: 57355
Accept-Ranges: bytes
Date: Thu, 11 May 2017 14:40:49 GMT
X-Varnish: 2041836058
Age: 0
Connection: close
X-Cache: MISS
Set-Cookie: BIGipServerws_drupalprd_pool=!3h7FurrSYo24UlzhZrY1cYfRyoiyA/5lmN6c9N3yHVZ8FB52aKDkt9EqTIjX3YFBReDiotpAiLdbwbY=; path=/
IP address in detail
The following domains are, too, hosted on 72.34.128.214:
Keywords
A total of 10 keywords are used by the website
- Herceptin
- PERJETA and Herceptin
- pertuzumab
- metastatic breast cancer treatment
- her2+
- PERJETA
- her2-positive metastatic breast cancer
- neoadjuvant
- mbc
- Genentech
List of related IP addresses
Based on A and B block, the following IP adresses are similar to 72.34.128.214
Domain extension options
The following domain extensions are available for the domain name, with a total of 730 variations available:
Global Alexa rating
As mentioned by Alexa on their official page, the Alexa rank or rating is calculated using a number of different parameters, such as daily average of unique visitors as well as pageviews over the last three months. The more unique visitors and pageviews, the higher the overall rank.
Unfortunately, our database contains no Alexa rank data for Perjeta.com at this time.
Website domain mistypes
Visitors frequently mistype perjeta.com.
Here is a list of most common misspellings:
Domain history
It seems perjeta.com has only been registered once and was never abandoned or has never expired.
Rating by Quantcast
Established in 2006, the technology company Quantcast provides audience measurements and an opportunity for advertising in real time. In addition to that, the American company ensures public access to all sorts of website-related data (traffic and demographic) for millions of websites, as well as in-depth user insights to digital bloggers and publishers enrolled in Quantcast's Quantified Publisher Program. The processing capability provided by Quantcast is impressive – over 800 thousand transactions per second, with, as claimed by the company, accurate audience calculation for over 100 million online destinations. In 2013, Quantcast was widely believed to be among the top five of world's largest data processing companies. Holding offices in London, Dublin, New York and Chicago, the main headquarters of Quantcast is in San Francisco, CA.
Perjeta.com
Current rating: | spotted 3,782 days ago |
---|
Worst rating: | spotted 3,802 days ago |
---|
Best rating: | spotted 3,783 days ago |
---|
Average rating: | |
---|